US FDA Pushing Coronavirus Trial Sponsors To Include Control Groups
“We still try hard to get people to have a control group,” Bob Temple says in an interview. “Not everybody always wants to have a control group. We've been trying hard to do it.”
You may also be interested in...
The coronavirus pandemic could be a turning point for master protocol and platform trial designs, but clear guidance and coordination are still needed.
Based on experience from earlier epidemics, EU regulators are concerned that the high number of COVID-19 trials starting in a confined geography at the peak of the coronavirus pandemic will not be able to enrol patients up to their pre-established sample size.
Final guidance on COVID-19 treatment development emphasizes need for clinical endpoints to reflect drug mechanism, patient population, clinical setting and fast-evolving standard of care – with a cautious embrace of platform and adaptive designs.